These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy. Pierot L; Desnos C; Blin J; Raisman R; Scherman D; Javoy-Agid F; Ruberg M; Agid Y J Neurol Sci; 1988 Sep; 86(2-3):291-306. PubMed ID: 2975699 [TBL] [Abstract][Full Text] [Related]
23. Neuropathology of variants of progressive supranuclear palsy. Dickson DW; Ahmed Z; Algom AA; Tsuboi Y; Josephs KA Curr Opin Neurol; 2010 Aug; 23(4):394-400. PubMed ID: 20610990 [TBL] [Abstract][Full Text] [Related]
24. Distinct patterns of brain activity in progressive supranuclear palsy and Parkinson's disease. Burciu RG; Ofori E; Shukla P; Planetta PJ; Snyder AF; Li H; Hass CJ; Okun MS; McFarland NR; Vaillancourt DE Mov Disord; 2015 Aug; 30(9):1248-58. PubMed ID: 26148135 [TBL] [Abstract][Full Text] [Related]
25. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457 [TBL] [Abstract][Full Text] [Related]
26. Clinical progressive supranuclear palsy: differential diagnosis by IBZM-SPECT and MRI. Arnold G; Tatsch K; Oertel WH; Vogl T; Schwarz J; Kraft E; Kirsch CM J Neural Transm Suppl; 1994; 42():111-8. PubMed ID: 7964681 [TBL] [Abstract][Full Text] [Related]
27. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429 [TBL] [Abstract][Full Text] [Related]
28. Astrocytic pathology in progressive supranuclear palsy: significance for neuropathological diagnosis. Matsusaka H; Ikeda K; Akiyama H; Arai T; Inoue M; Yagishita S Acta Neuropathol; 1998 Sep; 96(3):248-52. PubMed ID: 9754957 [TBL] [Abstract][Full Text] [Related]
29. Neurotensin receptors in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study in basal ganglia. Chinaglia G; Probst A; Palacios JM Neuroscience; 1990; 39(2):351-60. PubMed ID: 1965015 [TBL] [Abstract][Full Text] [Related]
30. Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains. Ingelsson M; Ramasamy K; Russ C; Freeman SH; Orne J; Raju S; Matsui T; Growdon JH; Frosch MP; Ghetti B; Brown RH; Irizarry MC; Hyman BT Acta Neuropathol; 2007 Nov; 114(5):471-9. PubMed ID: 17721707 [TBL] [Abstract][Full Text] [Related]
31. Different tau pathology pattern in two clinical phenotypes of progressive supranuclear palsy. Jellinger KA Neurodegener Dis; 2008; 5(6):339-46. PubMed ID: 18349518 [TBL] [Abstract][Full Text] [Related]
32. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Foster NL; Gilman S; Berent S; Morin EM; Brown MB; Koeppe RA Ann Neurol; 1988 Sep; 24(3):399-406. PubMed ID: 3265862 [TBL] [Abstract][Full Text] [Related]
33. Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: analysis with [(123)I]IPT single photon emission computed tomography. Im JH; Chung SJ; Kim JS; Lee MC J Neurol Sci; 2006 May; 244(1-2):103-9. PubMed ID: 16473371 [TBL] [Abstract][Full Text] [Related]
34. Brain amino acids and glutathione in progressive supranuclear palsy. Perry TL; Hansen S; Jones K Neurology; 1988 Jun; 38(6):943-6. PubMed ID: 3368077 [TBL] [Abstract][Full Text] [Related]
35. Increased basal ganglia binding of Smith R; Schain M; Nilsson C; Strandberg O; Olsson T; Hägerström D; Jögi J; Borroni E; Schöll M; Honer M; Hansson O Mov Disord; 2017 Jan; 32(1):108-114. PubMed ID: 27709757 [TBL] [Abstract][Full Text] [Related]
37. Dopamine receptors in human brain: autoradiographic distribution of D1 and D2 sites in Parkinson syndrome of different etiology. Cortés R; Camps M; Gueye B; Probst A; Palacios JM Brain Res; 1989 Mar; 483(1):30-8. PubMed ID: 2650806 [TBL] [Abstract][Full Text] [Related]
38. Differential distribution of striatal [123I]beta-CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography. Messa C; Volonté MA; Fazio F; Zito F; Carpinelli A; d'Amico A; Rizzo G; Moresco RM; Paulesu E; Franceschi M; Lucignani G Eur J Nucl Med; 1998 Sep; 25(9):1270-6. PubMed ID: 9724376 [TBL] [Abstract][Full Text] [Related]
39. A comparative immunohistochemical study on striatal Met-enkephalin expression in Alzheimer's disease and in progressive supranuclear palsy. Matsumoto S; Goto S; Hirano A Acta Neuropathol; 1990; 81(1):74-7. PubMed ID: 2085095 [TBL] [Abstract][Full Text] [Related]
40. The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy. Mann DM; Oliver R; Snowden JS Acta Neuropathol; 1993; 85(5):553-9. PubMed ID: 8493863 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]